BiotechTube
Home/Nanomerics/Dr. Andreas G. Schätzlein
DA

Dr. Andreas G. Schätzlein

CEO & Co-founder

Nanomerics

Therapeutic Areas

OphthalmologyCentral Nervous System (CNS)

Nanomerics Pipeline

DrugIndicationPhase
OC134Ophthalmology (unspecified)Phase 1
Envelta™ (NB127)Non-addictive analgesic (CNS)Partnered (Virpax)
METfect PlatformGenetic CNS disordersPre-clinical

Leadership Team at Nanomerics

DI
Dame Ijeoma Uchegbu
CSO & Co-founder
AM
Andrea Mica
Non-Executive Director
DA
Dr. Alan Bye
Non-Executive Director
View full Nanomerics profile